Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
PurposePlatinum-based chemotherapy remains the classic treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who progress while receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). In this study, we analyzed real-world outcomes of...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.700023/full |
| _version_ | 1819105463932813312 |
|---|---|
| author | Haiyi Deng Xinqing Lin Xiaohong Xie Yilin Yang Liqiang Wang Jianhui Wu Ming Liu Zhanhong Xie Yinyin Qin Chengzhi Zhou |
| author_facet | Haiyi Deng Xinqing Lin Xiaohong Xie Yilin Yang Liqiang Wang Jianhui Wu Ming Liu Zhanhong Xie Yinyin Qin Chengzhi Zhou |
| author_sort | Haiyi Deng |
| collection | DOAJ |
| description | PurposePlatinum-based chemotherapy remains the classic treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who progress while receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). In this study, we analyzed real-world outcomes of treatment with immune checkpoint inhibitors (ICIs) combined with platinum-free chemotherapy in patients with NSCLC after developing resistance to EGFR-TKIs.MethodsThis retrospective study included patients with mutation-positive NSCLC after developing resistance to EGFR-TKIs. Patients who received chemotherapy alone plus ICIs with or without anti-angiogenic drugs (cohort A) or platinum-based chemotherapy (cohort B) between February 2019 and August 2020 were enrolled. Clinical characteristics, EGFR mutation status, response to therapy, and adverse events (AEs) were retrospectively analyzed.ResultsSeventeen patients were eligible and included in the analysis, including 8 in cohort A and 9 in cohort B. After a median follow-up of 7.6 months, the median progression-free survival was 6.5 months [95% confidence interval (CI), 6.1 to 7.0] in cohort A and 3.6 months (95% CI, 1.3–5.8) in cohort B (hazard ratios, 0.22; 95% CI, 0.05–0.93; P = 0.039). The overall response and disease control rates were 50% and 100% in cohort A, and 22% and 89% in cohort B, respectively. Adverse events of grade 3 or higher occurred in 25% of the patients in cohort A and in 33.3% of the patients in cohort B.ConclusionICIs plus platinum-free, single-agent chemotherapy provides promising progression-free survival and overall response rate benefit, along with a low rate of severe AEs in patients with EGFR-TKI-resistant advanced NSCLC. |
| first_indexed | 2024-12-22T02:22:39Z |
| format | Article |
| id | doaj.art-ea11f7d37e244f1fa67e5b791f543b30 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T02:22:39Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ea11f7d37e244f1fa67e5b791f543b302022-12-21T18:42:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.700023700023Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKIHaiyi DengXinqing LinXiaohong XieYilin YangLiqiang WangJianhui WuMing LiuZhanhong XieYinyin QinChengzhi ZhouPurposePlatinum-based chemotherapy remains the classic treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who progress while receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). In this study, we analyzed real-world outcomes of treatment with immune checkpoint inhibitors (ICIs) combined with platinum-free chemotherapy in patients with NSCLC after developing resistance to EGFR-TKIs.MethodsThis retrospective study included patients with mutation-positive NSCLC after developing resistance to EGFR-TKIs. Patients who received chemotherapy alone plus ICIs with or without anti-angiogenic drugs (cohort A) or platinum-based chemotherapy (cohort B) between February 2019 and August 2020 were enrolled. Clinical characteristics, EGFR mutation status, response to therapy, and adverse events (AEs) were retrospectively analyzed.ResultsSeventeen patients were eligible and included in the analysis, including 8 in cohort A and 9 in cohort B. After a median follow-up of 7.6 months, the median progression-free survival was 6.5 months [95% confidence interval (CI), 6.1 to 7.0] in cohort A and 3.6 months (95% CI, 1.3–5.8) in cohort B (hazard ratios, 0.22; 95% CI, 0.05–0.93; P = 0.039). The overall response and disease control rates were 50% and 100% in cohort A, and 22% and 89% in cohort B, respectively. Adverse events of grade 3 or higher occurred in 25% of the patients in cohort A and in 33.3% of the patients in cohort B.ConclusionICIs plus platinum-free, single-agent chemotherapy provides promising progression-free survival and overall response rate benefit, along with a low rate of severe AEs in patients with EGFR-TKI-resistant advanced NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2021.700023/fullepidermal growth factor receptor gene (EGFR)immune checkpoint inhibitorimmunotherapynon-small-cell lung cancersingle-agent chemotherapy |
| spellingShingle | Haiyi Deng Xinqing Lin Xiaohong Xie Yilin Yang Liqiang Wang Jianhui Wu Ming Liu Zhanhong Xie Yinyin Qin Chengzhi Zhou Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI Frontiers in Oncology epidermal growth factor receptor gene (EGFR) immune checkpoint inhibitor immunotherapy non-small-cell lung cancer single-agent chemotherapy |
| title | Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI |
| title_full | Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI |
| title_fullStr | Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI |
| title_full_unstemmed | Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI |
| title_short | Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI |
| title_sort | immune checkpoint inhibitors plus single agent chemotherapy for advanced non small cell lung cancer after resistance to egfr tki |
| topic | epidermal growth factor receptor gene (EGFR) immune checkpoint inhibitor immunotherapy non-small-cell lung cancer single-agent chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.700023/full |
| work_keys_str_mv | AT haiyideng immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT xinqinglin immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT xiaohongxie immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT yilinyang immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT liqiangwang immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT jianhuiwu immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT mingliu immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT zhanhongxie immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT yinyinqin immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki AT chengzhizhou immunecheckpointinhibitorsplussingleagentchemotherapyforadvancednonsmallcelllungcancerafterresistancetoegfrtki |